Podophyllotoxin derivatives

Details Podophyllotoxin derivatives Podophyllotoxin derivatives

2008-01-18

2009-10-20

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C549S299000

Reexamination Certificate

active

07605262

ABSTRACT:
4-O esters of podophyllotoxin and 4′-demethylepipodophyllotoxin are provided. The compounds are 4-O esters of an alkanoic acid or substituted alkanoic acid and podophyllotoxin and 4′-demethylepipodophyllotoxin. The compounds are useful for treating cancer.

REFERENCES:
patent: 3524844 (1970-08-01), Keller-Juslen
patent: 4965348 (1990-10-01), Saulnier et al.
patent: 5534499 (1996-07-01), Ansell
patent: 5614549 (1997-03-01), Greenwald et al.
patent: 5840900 (1998-11-01), Greenwald et al.
patent: 5880131 (1999-03-01), Greenwald et al.
patent: 6096336 (2000-08-01), Cao et al.
patent: 6251382 (2001-09-01), Greenwald et al.
patent: 7342114 (2008-03-01), Yang
patent: 2837824 (2002-03-01), None
patent: 1 114 123 (1968-05-01), None
patent: 01117885 (1989-01-01), None
patent: 01 117885 (1989-05-01), None
patent: 02300124 (1990-02-01), None
patent: WO 96/23794 (1996-08-01), None
patent: WO 98/07713 (1998-02-01), None
patent: WO 0001417 (2000-01-01), None
patent: WO 00/29427 (2000-05-01), None
patent: WO 0029427 (2000-05-01), None
patent: WO 0226220 (2001-09-01), None
patent: WO 0202804 (2002-06-01), None
patent: WO 02102805 (2002-12-01), None
patent: WO 03/082875 (2003-10-01), None
Gupta et al. Anti-Cancer Drug Design (1987), 2(1), 13-23.
Yang et al.STN Accession No. 2002:884382 Document No. 139:159531 Abstract of Lanzhou Daxue Xuebao, Ziran Kexueban (2002), 38(2), 101-105.
Xiao et al. STN Accession No. 2002:306357; Document No. 137:56983, Abstract of Journal of Medicinal Chemistry (2002),45(11), 2294-2309.
Thurston et al. Journal of Medicinal Chemistry (1989),32(3), 604-8.
Levy et al. Journal of Pharmaceutical Sciences (1983),72(10), 1158-61.
Greenwald et al.STN Accession No. 1999:568594; Document No. 132:15517, Abstract of Journal of Controlled Release (1999), 61(3), 281-294.
Shi et al. Bioorganic and Medicinal Chemistry, 9 (2000), 2999-3004.
Xiao, et al., “Antitumor Agents. 213. Modeling of Epipodophyllotoxin Derivatives Using Variable Section k Nearest Neighbor QSAR Method,” Journal of Medicinal Chemistry (2002), 45(11), 2294-2309, CODEN: JMCMAR; ISSN: 0022-2623, American Chemical Society, Natural Products Laboratory Division of Medicinal Chemistry and Natural Products School of Pharmacy, Chapel Hill, North Carolina.
Li et al., “Reactions of podophyllotoxin with DDQ,” Chinese Chemical Letters (2001), 12(12), 1057-1060, CODEN: CCLEE7; ISSN: 1101-8417, Chinese Chemical Society, Structure Research Laboratory, University of Science and Technology of China, Hefei, China.
Pan et al., “Synthesis of epipodophyllotoxin carboxylates and antitumor activity in vitro,” Yaoxue Xuebao (1997), 32(12), 898-901, CODEN: YHHPAL; ISSN: 0513-4870, Chinese Academy of Medical Sciences, Institute of Materia Media, Department of Chemistry, Zhejian University, Hangzhou, China.
Pan et al., “Synthesis and antitumor activity of new derivatives of podophyllotoxin,” Current Science (1997), 72(4), 268-271, CODEN: CUSCAM; ISSN: 0011-3891, Current Science Association, Department of Chemistry, Zhejiang University, Hangzhou, China.
Cho et al., Antitumor Agents. 163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach, Journal of Medicinal Chemistry (1996), 39(7), 1383-95, CODEN: JMCMAR; ISSN: 0022-2623, American Chemical Society, School of Pharmacy, University of North Carolina, US.
Gan et al., “Inhibition of tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-β) secretion but not IL-6 from activated human peripheral blood monocytes by a new synthetic demethylpodophyllotoxin derivative,” Journal of Clilnical Immunology (1994), 14(5), 280-8, CODEN: JCIMDO; ISSN: 0271-9142, UCLA School Medicine, University California, US.
Yin et al., “Synthesis and antitumor activity of 4-O-(halogenated) acyl-4'-demethylepipodophyllotoxin analogs,” Yaoxue Xuebao (1993), 28(10), 758-61, CODEN: YHHPAL; ISSN: 0513-4870, Shanghai Inst. Pharm. Ind., Shanghai, China.
Gan et al., “Selective inhibition of TNF-alpha and IL-1-beta synthesis and secretion from activated human monocytes by a new synthetic demethylpodophyllotoxin derivative,” European Cytokine Network, (1994), vol. 5, No. 2, pp. 207; Meeting Info.: 5thInternational Congress on Tumor Mecrosis Factor, California, US, ISSN: 1148-5493.
Brodin, et al. “In vitro release studies on lidocaine aqueous solutions, micellar solutions, and o/w emulsions”.Acta Pharm Suec. 19: 267-284 (1982).
Fischer, et al. “Preparation of peptide derivatives for improved delivery of drug therapeutic agents”. Abstract, CA 132:93654 (2000).
Forssen, et al. “Selective in Vivo Localization of Daunorubicin Small Unilamellar Vesicle in Solid Tumors”.Cancer Res, 52: 3255-3261 (1992).
Fung, et al. “Perfluorochemical Emulsions with Fluorinated Surfactants and Anticancer Drugs”.Biomater. Artif. Cells. Artif. Organs16(1-3): 439-440 (1988).
Gensler, et al. “Nonenolizable Podophyllotoxin Derivates”.J. Med. Chem. 20(5): 635-644 (1977).
Greenwald, et al. “Drug delivery of anticancer agents: water soluble 4-polyethylene glycol derivatives of the lignan, podophyllotoxin.” Abstract, CA 132:15517 (1999).
Hansen, et at. “New Compounds Related to Podophyllotoxin and Congeners: Synthesis, Structure Elucidation and Biological Testing”.Acta Chemi. Scand.47: 1190-1200 (1993).
Khokhar, et al. “Chemical and Biological Studies on a Series of Lipid-Soluble (trans-(R,R)- and -(S,S)-1,2- Diaminocyclohexane)platinum(II) Complexes Incorporated in Liposomes”.J. Med. Chem, 34: 325-329 (1991).
Lasic. “Mixed micelles in drug delivery”.Nature335: 279-280 (1992).
Lee, et al. “Anti-aids Agents. 29. Anti-HIV Activity of Modified Podophyllotoxin Derivatives”.Bio & Med. Chem. Ltrs. 7(22): 2897-2902 (1997).
Levy, et al. “Antitumor agents. LXII: Synthesis and biological evaluation of podophyllotoxin esters and related derivatives”.J. Pharm. Sci. 72(10): 1158-1161(1983).
Lie, et al. “Synthesis and spectral characteristics of some unusual fatty esters of podophyllotoxin”. CA 132:3273.
Mantle. “Therapeutic applications of medicinal plants in the treatment of breast cancer: a review of their pharmacology, efficacy and tolerability”. PMID: 11059361 (2000).
Nagao, et al. “Different mechanisms of action of long chain fatty acid esters of podophyllotoxin and esters of epipodophyllotoxin against P388 lymphocytic leukemia in mice.” Medicinal Chemistry Research, 1(4): 295-9 (1991).
Nagao, et al. “Preparation and testing of podophyllotoxin derivatives as neoplasm inhibitors.” CA 112:7272 (1990).
Pan, et al. “Synthesis of epipodophyllotoxin carboxylates and antitumor activity in vitro”. Abstract, CA 129: 175488 (1998).
Pan, et al. STN Accension No. 1998:291310; Document No. 129:175488; Abstract of Yaoxue Xuebao, 1997, 32(12), 898-901.
Perez-Soler, et al. “Anthracycline Antibodies with High Liposome Entrapment: Structural Features and Biological Activity”.Cancer Res., 50:4260-4266 (1990).
Pradhan. “SN Effect of Various Drugs on the Tumor-necrotizing Activity of Several Chemical Agents in Mice”. Cancer Research (1956) 1062-8.
Santangelo, et al. “A convenient synthesis of phosphate esters of dopamine and epinine”.Syn. Comm., 26(15): 2863-2873 (1996).
Supersaxo, et al. “Mixed Micelles as a Proliposomal, Lymphotropic Drug Carrier”.Pharm Res. 8(10): 1280-1291 (1991).
Thurston, et al. “Antitumor Agents. 100. Inhibition of Human DNA Topoisomerase II by Cytotoxin Ether and Ester Derivatives of Podophyllotoxin and α-Peltatin”.J. Med. Chem. 32: 604-608 (1989).
Wang, et al. “Syntheses and structure-activity relationship of podophyllotoxin derivatives as potential anticancer drugs”. Abstract, CA 127:149030 (1997).
Weller, et al. “21

Affiliated with

Also associated with

Rating

Podophyllotoxin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Podophyllotoxin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Podophyllotoxin derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4102610